108 related articles for article (PubMed ID: 1578361)
1. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
Kinter LB; McConnell I; Goodwin BT; Campbell S; Huffman WF; Arthus MF; Lonergan M; Bichet DG
J Pharmacol Exp Ther; 1992 May; 261(2):462-9. PubMed ID: 1578361
[TBL] [Abstract][Full Text] [Related]
2. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
Bichet DG; Razi M; Lonergan M; Arthus MF; Papukna V; Kortas C; Barjon JN
N Engl J Med; 1988 Apr; 318(14):881-7. PubMed ID: 2965301
[TBL] [Abstract][Full Text] [Related]
4. Flushing and haemodynamic responses to vasopressin peptides in the rhesus monkey.
Brooks DP; Koster PF; Stassen FL; Albrightson CR; Huffman WF; Wasserman MA; Kinter LB
Br J Pharmacol; 1988 Jul; 94(3):759-64. PubMed ID: 3179611
[TBL] [Abstract][Full Text] [Related]
5. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
6. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.
Kaufmann JE; Oksche A; Wollheim CB; Günther G; Rosenthal W; Vischer UM
J Clin Invest; 2000 Jul; 106(1):107-16. PubMed ID: 10880054
[TBL] [Abstract][Full Text] [Related]
8. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.
Lethagen S; Harris AS; Sjörin E; Nilsson IM
Thromb Haemost; 1987 Dec; 58(4):1033-6. PubMed ID: 3127915
[TBL] [Abstract][Full Text] [Related]
9. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta).
Brooks DP; Koster PF; Albrightson-Winslow CR; Stassen FL; Huffman WF; Kinter LB
J Pharmacol Exp Ther; 1988 Apr; 245(1):211-5. PubMed ID: 3361442
[TBL] [Abstract][Full Text] [Related]
10. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
[TBL] [Abstract][Full Text] [Related]
11. DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
Derkx FH; Man in 't Veld AJ; Jones R; Reid JL; Schalekamp MA
J Hypertens Suppl; 1983 Dec; 1(2):58-61. PubMed ID: 6400119
[TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells.
Hashemi S; Palmer DS; Aye MT; Ganz PR
J Cell Physiol; 1993 Mar; 154(3):496-505. PubMed ID: 8436598
[TBL] [Abstract][Full Text] [Related]
13. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
14. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
Moffat EH; Giddings JC; Bloom AL
Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
[TBL] [Abstract][Full Text] [Related]
15. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
Brommer EJ; Derkx FH; Barrett-Bergshoeff MM; Schalekamp MA
Thromb Haemost; 1984 Feb; 51(1):42-4. PubMed ID: 6426080
[TBL] [Abstract][Full Text] [Related]
16. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
Vicente V; Alberca I; Mannucci PM
Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
[No Abstract] [Full Text] [Related]
17. Mechanism of arginine vasopressin suppression of ovine fetal lung fluid secretion: lack of V2-receptor effect.
Albuquerque CA; Nijland MJ; Ross MG
J Matern Fetal Med; 1998; 7(4):177-82. PubMed ID: 9730483
[TBL] [Abstract][Full Text] [Related]
18. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
[TBL] [Abstract][Full Text] [Related]
19. L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs.
Liard JF
Am J Physiol; 1994 Jan; 266(1 Pt 2):H99-106. PubMed ID: 8304528
[TBL] [Abstract][Full Text] [Related]
20. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
